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  ABSTRACT 
Working with curcuminoids, especially with the main curcuminoide named 
curcumin and formulate it to improve stability and solubility has been an 
ongoing ambition in the department of pharmacy, University of Oslo.  
Curcumin has an exceedingly low solubility in water. The aim of the present 
study was to use a selected cyclodextrin to increase the solubility of curcumin 
in aqueous solutions. The complexation between curcumin and randomized-
methylated-β-cyclodextrin was investigated in phosphate buffer at fixed pH 5. 
The influence of low amounts of alginate, HPMC 
(Hydroxypropylmethylcelluose) and ethanol on the complexation was then 
investigated.  
All studies show non-linear AP like curves, which indicates some kind of 
higher order complexation. The highest curcumin concentration obtained in 
the present study was a curcumin solubility of 1.77x10-4 M detected in 5% 
(w/v) RMβCD in phosphate buffer (1% (v/v) ethanol), which corresponds to 
an almost 6000x increase in curcumin solubility, which shows great promise. 
To further enhance the solubility of curcumin in aqueous solutions, a solvent 
evaporation method was selected. For that, a solution of curcumin powder in 
methanol containing RMβCD was prepared. After evaporation by a rotavapor 
curcumin is significantly more soluble in its amorphous form than it is before 
the evaporation in its crystalline form.  
An excess of this powder was then diluted with purified water and filtered. 
After filtration HPMC was dissolved in the filtrate and the solution was 
lyophilized by a freeze dryer. Here, the method of lyophilization was used to 
improve the physical and chemical stability of this solution. The drug load of 
this lyophilized product shows great promise for doing more investigations. 
	  
	  ABSTRACT 
Die Arbeit mit Curcuminoiden, insbesondere mit dem Hauptcurcuminoid 
Curcumin, ist ein permanentes Bestreben der Mitarbeiter des Departments 
der Pharmazie an der Universität Oslo, Norwegen. Deren Arbeit besteht 
darin, dieses genannte Curcumin herzustellen und es in seiner Stabilität und 
Löslichkeit zu verbessern. 
Curcumin besitzt eine äußerst geringe Wasserlöslichkeit. Das Ziel dieser 
Diplomarbeit besteht also darin, mit der Hilfe eines ausgesuchten 
Cyclodextrins die Löslichkeit von Curcumin in wässriger Lösung zu erhöhen. 
Die Komplexbildung des Curcumins mit dem randomisierten, methylierten β-
Cyclodextrin wurde in Phosphatpuffer bei einem fixen pH von 5 durchgeführt. 
Weiters wurde der Einfluss von geringen Mengen von Alginaten und HPMC, 
als auch der Einfluss von Ethanol auf die Komplexbildung untersucht. 
Alle Untersuchungen zeigten nicht lineare Ap Kurven, welche 
Komplexbildungen höherer Art bedeuten. Die höchste Curcumin-
konzentration, welche in dieser ganzen Arbeit erlangt wurde, war eine 
Curcuminlöslichkeit von 1.77x10-4 M, die in 5% (w/v) RMβCD in 
Phosphatpuffer (1% (v/v) Ethanol) gefunden wurde. Dies bedeutet eine fast 
6000-fache Erhöhung der Curcuminlöslichkeit, welches sehr 
vielversprechend scheint. 
Um eine weitere Erhöhung der Löslichkeit von Curcumin in wässriger Lösung 
zu erzielen, wurde ein Lösungsmittelverdampfungsverfahren gewählt. Dieses 
Verfahren wurde mit einem Rotavapor durchgeführt. Hierzu wurde eine 
Lösung angefertigt bestehend aus Curcuminpulver und RMβCD, welche in 
Methanol gelöst sind. Curcumin zeigte nach diesem Verdampfungsverfahren 
eine deutlichere Erhöhung seiner Löslichkeit, was möglicherweise an seiner 
amorphen Form lag, im Unterschied zu davor, als Curcumin in seiner 
kristallinen Form vorlag.  
 
	  
	  Ein Teil dieses Pulvers wurde in destilliertem Wasser gelöst und filtriert. In 
diesem Filtrat wurde HPMC weitgehend aufgelöst und diese Lösung in einer 
Gefriertrocknungsanlage lyophilisiert. Die Wirkstoffbeladung dieses 
lyophilisierten Produktes scheint äußerst vielversprechend und ermutigt das 
Team in Oslo mit den Untersuchungen fortzufahren. 
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1 AIM OF THE STUDY 
The aim of the present study was to improve the aqueous solubility and 
dissolution rate of curcumin by using a selected MβCD. 
Further, to investigate the effect of low amounts of alginate, HPMC and 
ethanol on the Cur : CD complexation. 
2	  
	  
2 INTRODUCTION 
2.1 CURCUMIN 
2.1.1 Natural occurrences of curcumin 
Curcumin is a naturally occurring compound and the commercially available 
curcumin is isolated from the plant Curcuma longa L., belonging to the 
Zingiberaceae family (Tomren, M.A., et al., 2007; Jayaprakasha, G.K., et al., 
2005; Tønnesen H.H. et al., 2002a). This plant is widely cultivated in warm, 
rainy regions of the world such as China, India, Indonesia, Jamaica and Peru 
(Jayaprakasha, G.K., et al., 2005). 
The coloring principle of turmeric was isolated in the 19th century and was 
named curcumin. Three Curcuminoids were isolated from turmeric viz., 
curcumin, demethoxycurcumin and bisdemethoxycurcumin (Jayaprakasha, 
G.K., et al., 2005). 
The curcumin on the market consists of a mixture of these three naturally 
occurring curcuminoids, with curcumin as the main constituent (Tønnesen, 
H.H., et al., 2002a). However, to avoid interference from other curcuminoides 
(i.e. demethoxycurcumin and bisdemethoxycurcumin) the curcumin used in 
the present study is synthesized with the method of Pabon (Pabon, H., 
1964). The purity of curcumin has previously been controlled with HPLC, TLC 
and DSC (Haukvik, T., et al., 2009). 
 
 
Figure 1: The chemical structure of curcumin 
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2.1.2 Use of curcumin 
Curcuma has been used in Asian medicine since the second millennium BC. 
It also has been referred to the ancient Hindu scripture, the Ayurveda 
(Sharma, R.A., et al. 2007). There turmeric has been used internally as a 
stomachic, tonic and blood purifier and externally in the prevention and 
treatment of skin diseases (The Wealth of India, 2001; Jayaprakasha, G.K., 
et al. 2005). 
Further, curcumin is used as a coloring agent in food, drugs and as well as in 
cosmetics and textiles. Curcumin is one of the constituents of curry powder 
(Govindarajan, V.S., 1980). 
 
2.1.3 Physio-chemical properties of curcuminoids 
2.1.3.1 Structure of curcumin 
Curcumin is a symmetric molecule with two aromatic rings with ortho 
methoxy fenolic –OH groups and a diketone moiety (figure 1). The diketone 
moiety can undergo keto-enol tautomerization depending on the solvent and 
temperature as summarized in the reference (Priyadarsini, K.I., 2009). Figure 
2 shows the keto-enol tautomerization of curcumin. In solution, the cis-enol 
configuration of curcumin is stabilized by a strong intramolecular H-bond. 
This intramolecular bonding gives the enol ring a pseudo aromatic character 
(Tønnesen, H.H., et al., 1982). 
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Figure 2: The keto-enol tautomerization of curcumin (Singh, R., 2008) 
 
2.1.3.2 Pharmacological effects and Pharmacokinetics of 
curcumin 
Curcumin has a number of pharmacological effects (Tønnesen H.H. et al., 
2002a). In vitro studies show potential use against cancer, HIV-infections, 
cystic fibrosis and as an immunmodulating agent (Chattopadhyay, I., et al., 
2004; Jayaprakasha, G.K., et al., 2005). 
Other reported biological activities in vivo of curcumin include anti-
inflammatory activity, antioxidant, antibacterial effect against Alzheimer’s 
disease and antimicrobial activity, which is shown in vitro (Tønnesen, H.H., et 
al., 1987; Chattopadhyay, I., et al., 2004; Jayaprakasha, G.K., et al., 2005) 
Curcumin has a potential as a photosensitizer in antimicrobial photodynamic 
therapy (PDT) of localized superficial infections (Haukvik, T., et al., 2009; 
Hegge, A.B., et. al, 2010). 
Pharmacologically curcumin is well tolerated even at a dose of 8 g/day orally.  
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2.1.3.3 Solubility and stability of curcumin – challenges of using 
curcumin 
One of the challenges of making a formulation of curcumin is the compounds 
stability (Hegge, A.B., 2010). It is influenced by pH, light, temperature, 
chemical oxidants, metal ions, enzymes and solvents (Lauro, G.J., et al., 
2000).  
One of the main drawbacks is that curcumin is almost insoluble in water at 
acidic and neutral pH (pH 1-7). The lipophilic character of the compound is 
the reason of the low water solubility. This limits the use as a drug, as 
mentioned before (Tønnesen, H.H., Karlsen, J., 1985a,b; Lauro, G.J., et al., 
2000; Tønnesen, H.H., 2006).  
To date, curcumin is not approved as a drug. Probably one of the reasons is 
its very low water solubility at physiological conditions as mentioned before 
and a corresponding low absorption after oral or i.v. administration. 
Furthermore, curcumin undergoes fast metabolism, resulting in low 
bioavailability (Priyadarsini, K.I., 2009). Also animal studies have shown that 
curcumin is rapidly metabolized, conjugated in the liver, and excreted in the 
feces. Accordingly, the low bioavailability, rapid plasma clearance and 
conjugation may be important limiting factors for medical application of 
curcumin (Lin, Xie, et al., 2010). 
On the other hand curcumin shows increased solubility in aqueous solvents 
with pH values over neutral, but is then highly susceptible to hydrolytic 
degradation, which means that it degrades under exposure to light 
(Tønnesen, H.H., Karlsen, J., 1985a,b; Lauro, G.J., et al., 2000; Tønnesen, 
H.H., 2002, Tønnesen, H.H., 2006). At pH 5 the hydrolytic degradation rate of 
curcumin is low (Tønnesen, H.H., Karlsen, J., 1985b). Curcumin in its solid 
state shows photodegradation. Radiation wavelengths from 280-450nm 
initiate singlet oxygen production, which cause degradation of the 
curcuminoids (Lauro, G.J., et al., 2000). Previous studies, which were 
performed to enhance the stabilization of curcumin against photochemical 
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degradation, have shown that it is a difficult task (Tønnesen, H.H., 2002; 
Tønnesen, H.H., et al., 2002a; Tomren, M.A., et al., 2007). 
Summarized, the pH influences the ionization, the rate of degradation and 
the color of curcumin. In neutral form (pH 1-7) the color is yellow; pH below 1 
and pH above 7.5 gives a red color (Tønnesen, H.H., Karlsen, J., 1985a,b; 
Lauro, G.J., et al., 2000; Tønnesen, H.H., 2006). The main degradation 
products are feruloylmethane, ferulic acid and vanillin. Alkaline degradation 
of curcumin also results in condensation products of feruloylmethane 
(Tønnesen, H.H., Karlsen, J., 1985a). 
Accordingly, the main drawbacks for clinical applications of curcumin are its 
low solubility at acidic and neutral pH, its low photostability, its rapid plasma 
clearance and conjugation and as well its poor bioavailability. 
Therefore, solubility and hydrolytic stability have been improved by making 
complex formation with cyclodextrins and micelles. Cyclodextrins are used in 
this thesis to increase the water solubility of curcumin in its neutral and most 
stable form (Tønnesen, H.H., Karlsen, J., 1985b). In fact, the solubility is 
increased by a factor of at least 104 at pH5 (Tønnesen, H.H., 2002; 
Tønnesen, H.H., et al., 2002a). 
 
7	  
	  
2.2 CYCLODEXTRIN 
2.2.1 Structure and characteristics of cyclodextrin 
As already mentioned above, the solubility of curcumin is an important 
drawback working with curcumin. To enhance the solubility of curcumin, CDs 
or different types of polymer can be used in order to improve the water 
solubility. 
Researchers try to investigate the benefits of complexing curcumin with other 
substances to increase systemic bioavailability (Lin, Xie, et al., 2010). For 
example they increase the systemic bioavailability by encapsulation in 
polymeric nanoparticles (Bisht, S., et al., 2007), surfactants (micelles) 
(Tønnesen, H.H., 2002) or cyclodextrins (Tønnesen, H.H., et al., 2002a), 
which are utilized in this thesis. 
The three most common naturally occurring CDs are α-cyclodextrin, β-
cyclodextrin and γ-cyclodextrin. They are cyclic (α-1,4)-linked 
oligosaccharides of α-D-glucopyranose with six, seven and eight units, 
respectively (Loftsson, T., et al., 1998). 
 
 
R: CH3 
Figure 3: chemical structure of randomly methylated-β-CD (Tønnesen, H.H., et al., 2002a) 
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CDs were first published in the year 1891 by the French scientist A. Villers. 
At this time he named them “cellulosine”. In 1903 the Austrian microbiologist 
Franz Schardinger published an article as well, where he describes two 
“crystalline dextrin”, which he had isolated from bacterial digest of potato 
starch. He identified his “crystalline dextrin” as Villers “cellulosine”. Later 
Schardinger changed the names to α-dextrin and β-dextrin (Loftsson, T., et 
al., 2007). 
 
 
Figure 4: Cone shape of cyclodextrins (Brewster, M.E., et al., 2007) 
 
Cyclodextrin molecules have a cylindrical, cone-like shape (Figure 4) with 
primary hydroxyl groups, which are located on the narrow side of the torus. 
They show a relative lipophilic central cavity while the secondary hydroxyl 
groups, which are located on the wider edge, having a hydrophilic outer 
surface (Loftsson, T., et al. 2005b; Loftsson, T., 1995). These hydroxyl 
groups on the outer surface are able to form hydrogen bonds with other 
molecules (Loftsson, T., et al., 2007a; Loftsson, T., et al., 2007b).  
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With their lipophilic cavity the CDs are able to form inclusion complexes with 
lipophilic compounds in aqueous solutions, which is discussed in detail in 
section 2.3.  
Such inclusion complexation will influence the physiochemical properties of 
the drug, for example aqueous solubility and stability (Loftsson, T., et al., 
2004a; Loftsson, T., et al. 2005b; Hegge, A.B., et al., 2008). 
 
2.2.2 Physio-chemical properties of β-cyclodextrin 
Even though the natural CDs are relatively hydrophilic, in particular β-
cyclodextrin, they have limited aqueous solubility because of the relatively 
strong binding of the natural CD molecules in the crystal state. Therefore a 
huge number of cyclodextrin derivatives with high solubility in water have 
been synthesized. The main reason for the increased solubility is that the 
random substitution transforms the crystalline CDs into amorphous mixtures 
of isomeric derivatives (Szejtli, J., 1988; Loftsson, T., et al., 1996a; Loftsson, 
T., et al., 1998; Brewster, M.E., et al., 2007).  
One of them is methyl-β-cyclodextrin. This selected CD was taken for the 
investigations in this thesis. 
 
2.2.3 Application and current use of cyclodextrins 
As pharmaceutical excipients, cyclodextrins are used to increase the 
aqueous solubility of poorly water-soluble, lipophilic substances (Loftsson, T., 
et al., 2002a; Loftsson, T., et al., 2007a).  
Furthermore, they are used to increase the stability of drugs in aqueous 
preparations. The use of CDs is often preferred to organic solvents in 
parenteral and topical formulations, to enhance oral bioavailability, to reduce 
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or prevent gastrointestinal or ocular irritation, reduce or eliminate unpleasant 
smells or tastes, to increase dermal availability of drugs or even to convert 
oils and liquid drugs into microcrystalline or amorphous powders (Loftsson, 
T., et al., 1998; Loftsson, T., et al., 1996a; Loftsson, T., et al., 2002a; 
Loftsson, T., et al., 2005b; Loftsson, T., et al., 2007a; Brewster, M.E., et al., 
2007). 
Methyl-β-cyclodextrin is relatively lipophilic compared to the natural β-CD, 
which is able to permeate mucosa and to enhance drug delivery through 
biological membranes, such as through the nasal mucosa, by reducing 
barrier function of the membranes (Martiin, E., et al. 1998). 
Because of the limited water solubility, natural β-cyclodextrin can’t be given 
parenterally. Also lipophilic CD derivatives, such as the methylated CDs, 
have been shown to be toxic after parenteral administration. The compound 
precipitate in the kidney and this can induce nephrotoxicity (Loftsson, T., et 
al., 1997; Loftsson, T., et al., 2005b).  
The oral administration of methylated β-cyclodextrin or methylated β-
cyclodextrin in topical formulations is somehow limited because of its 
potential toxicity but it is basically non-toxic when given in a low or moderate 
oral dosage. As a result β-cyclodextrin is being found in a number of oral, 
topical, buccal and rectal pharmaceutical formulations (Loftsson, T., et al., 
2005b; Brewster, M.E., et al., 2007). 
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2.3 INCLUSION COMPLEXATION WITH CYCLODEXTRIN 
2.3.1 Inclusion complexation 
As already mentioned in 2.2.1, cyclodextrins are able to form inclusion 
complexes in aqueous solutions. The reason for this is the chair formation of 
the glucopyranose units. Lipophilic drug molecule or lipophilic moieties of the 
drug molecule are taken into the central cavity, where water-molecules are 
located and replace them (Loftsson, T., et al., 2004a; Loftsson, T., et al. 
2005b; Hegge, A.B., et al., 2008).  
Because of these characteristics CDs are able to interact through non-
covalent interactions with poorly water-soluble substances and form a 
mixture of inclusion and non-inclusion complexes in aqueous solutions 
(Loftsson, T., et al., 2004a; Loftsson, T., et al. 2005b; Hegge, A.B., et al., 
2008).  
As well the size and the chemical structure of the guest molecule affect the 
complex formation. Only relative apolar molecules with an appropriate size, 
which is not too large, are able to enter the cyclodextrin cavity. But also the 
size of the cyclodextrin cavity is important (Loftsson, T., 1995). 
The cyclodextrin molecules are relatively large (molecular weight ranging 
from almost 1000 to > 2000 Da) with a large number of hydrogen donors and 
acceptors and they are consequently poorly absorbed through biological 
membranes (Loftsson, T., et al., 2005). 
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2.3.2 Stoichiometry and association constant of compound-CD 
inclusion complex 
Dependent on the type and amount of drug and cyclodextrin, a lot of different 
complexes of drug-cyclodextrin molecules can be formed, which have 
different CD : drug ratios or stoichiometry (Eq. 1). 
  Km:n 
mCD + nD <--> CDm x Dn 
Eq. 1 (Brewster, M.E., et al., 2007) 
The association constant (Kc), also known as equilibrium constant (Km:n) 
specifies the stoichiometric ratio of the complex. For explanation m is the 
amount of substrate and n is the amount of ligand. In this case ligand is the 
drug (D) and substrate is the cyclodextrin (CD). Thus m:n is the stoichiometry 
between substrate and ligand. For complexation, the association constant 
can be written: 
Km:n= [CDm x Dn ] / [CD]m  [D]n 
Eq. 2: (Brewster, M.E., et al., 2007) 
 
In dilute solutions, the most common stoichiometry of drug-cyclodextrin 
complex is 1:1 complexation, where one drug molecule (substrate) forms a 
complex with one cyclodextrin molecule (ligand) (Eq. 1). This occurs if the 
drug fits entirely into the cyclodextrin cavity and/ or in dilute solutions. In 
many cases such as for curcumin it is only a part of the drug, which is 
probably included in the CD cavity. The aromatic group of curcumin is a 
typical group, which fits into the beta CD cavity. Other ratios are for example 
1:2, 2:1 or 2:2. If the size of the drug is larger, two or more cyclodextrin 
molecules can enclose the drug and a 1:2 stoichiometry occurs or higher 
order complexes can be formed. If the cyclodextrin cavity incorporates 2 drug 
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molecules a formation of a 2:1 complex results (Connors, K.A., 1997; 
Frömming and Szejtli, 1994; Loftsson, T., et al. 2007b; Singh, R., 2008; 
Singh, R., et al. 2010). 
 
2.3.3 Method to determine stoichiometry and association constant 
of the inclusion complex: The phase solubility method 
The phase solubility method is a method to determine associations constants 
and stoichiometry of the equilibrium (Higuchi, T. and Connors, K.A., 1965). 
The exact procedure of the phase solubility method is described in section 
3.2.4. 
 A phase solubility diagram (figure 5) is constructed by plotting the total molar 
concentration of dissolved solute, found on the vertical axis. On the 
horizontal axis there is the concentration of the complexing agent added 
(Higuchi, T. and Connors, K.A., 1965; Brewster, M.E., et al., 2007). 
 
Figure 5: Phase solubility diagram (Brewster, M.E., et al., 2007) 
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In general, phase solubility diagrams have two major types: A- and B-types.  
A-type phase-solubility profiles are obtained when soluble complexes are 
formed. The A-curves are again subdivided into AL, AP and AN subtypes. AL 
profiles indicate a linear increase in solubility as a function of cyclodextrin 
concentration. AP profiles indicate positively deviating isotherm and AN 
indicate a negatively deviating isotherm. AL type diagrams are first order with 
respect to the cyclodextrin and may be first or higher order with respect to the 
drug, i.e., DCD, D2CD, D3CD,…, DmCD. If the slope of an AL-type profile is 
greater than one, higher order complexes are assumed to be involved. 
Although a slope less than one, does not necessarily exclude higher order 
complexation. Often a one-to-one complex is assumed. AP type diagrams 
suggest the formation of higher order complexes with respect to the 
cyclodextrin at higher cyclodextrin concentrations, i.e., DCD2, DCD3,…,DCDN 
(Brewster, T., et al. 2007; Loftsson, T., et al., 2005; Loftsson, T., et al., 
2004b; Singh, R., 2008). 
 
Complexation efficiency 
A more accurate method for determination the solubilizing effect of 
cyclodextrins is to compare their complexation efficiency (CE). The 
complexation efficiency is the determination of the concentration ratio 
between cyclodextrin in a complex and free cyclodextrin. It is calculated from 
the slope of the phase-solubility diagram and is independent of both SO 
(intrinsic solubility) and Sint (intersept) (Loftsson, T., et al., 2007b).  
 
Methods to enhance the complexation efficiency 
There are several reasons for increasing the efficiency of cyclodextrin 
complexation of drugs. For example toxicological considerations, production 
costs, drug bioavailability and isotonicity are just a few reasons why to 
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include as little cyclodextrin as possible in pharmaceutical formulations 
(Loftsson, T., et al., 1999; Loftsson, T., et al., 2005a; Loftsson, T., et al., 
2007a; Brewster, M.E., et al., 2007). 
Several methods have been applied to enhance the complexation efficiency 
of cyclodextrins (Loftsson, T., et al., 1999). For example, addition of different 
types of polymer like HPMC or sodium alginate to the aqueous complexation 
media (Loftsson, T., et al., 2004a), addition of co-solvents and so on (Li, P., 
et al., 1998; Loftsson, T., et al., 1999; Brewster, M.E., et al., 2007). 
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2.4 INCREASING THE SOLUBILITY OF CURCUMIN 
As mentioned above, the low solubility of curcumin limits its use as a drug. 
Cyclodextrins alone or in combination with water-soluble biopolymers is 
therefore used to enhance the solubility of curcumin. 
Adding a small amount of water-soluble polymer can increase the 
complexing abilities of β-cyclodextrin in aqueous solution and thus improve 
the solubility (Loftsson, T., et al. 1996b; Loftsson, T., et al. 1994; Loftsson, T., 
et al. 1998). 
In the present study sodium alginate and HPMC were chosen as polymer. 
Alginates are natural water-soluble polysaccharide polymers isolated from 
marine brown algae (Phaeophyceae) or fermentation of bacteria (Draget, 
K.I., et al., 2006). Alginic acid is a linear polymer consisting of D-mannuronic 
acid and L-glucuronic acid (Tønnesen, H.H., et al. 2002b). A number of 
different grades of sodium alginate, which have different solution viscosities, 
are available. Sodium alginate is practically insoluble in organic solvents and 
slowly soluble in water, forming a viscous colloidal solution. It is used in a 
variety of oral and topical pharmaceutical formulations, as stabilizing agent, 
suspending agent, viscosity-increasing agent and many more. In this study 
sodium alginate is used, which is probably the most frequently investigated 
one (Hegge, A.B., et al., 2008; Handbook of pharmaceutical excipients, 
2003).  
Hydroxypropylmethylcellulose (HPMC) also known under the trade name 
Hypromellose is a partly O-methylated and O-(2-hydroxypropylated) 
cellulose. Depending upon the viscosity grade, Hypromellose is available in 
several grades. It is used as a viscosity-increasing agent, as well as 
stabilizing, suspending or coating agent. It is soluble in cold water, forming a 
viscous colloidal solution (Handbook of pharmaceutical excipients, 2003). 
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3 EXPERIMENTAL: MATERIALS AND METHODS 
 
3.1 MATERIALS 
Curcumin was synthesized according to the method of Pabon (Pabon, H., 
1964). 
 
Chemical Lot Number Supplier 
Citric Acid monohydride 08D150022 VWR International 
Potassium hydroxide 11293 Eka Nobel AB/ Nobel Industrier 
Sodium chloride 9D122/4 Norsk Medisinaldepot, Norway 
Methanol Chromasolv® (HPLC-grade) SZBA1195 Sigma-Aldrich Co./Chemie GmbH 
Ethanol  Norsk Medisinaldepot, Norway 
Sodium hydrogen phosphate dihydrate K91380845 819 Merck KGaA 
Disodium hydrogen phosphate dihydrate K27618980 020 Merck KGaA 
RM- β-cyclodextrin = Cavasol W7 M 71T051 Wacker Chemie AG 
Hydroxypropylmethylcellulose 8028204 Shin-Etr Chemie. Lv. 
Sodium Alginate (Protanal® LF 10/60 LS)   S17261 FMC BioPolymers/NovaMatrix 
 
Table 1: all chemicals used in this thesis with Lot Number and Suppllier 
 
All chemicals used, were of analytical grade, except the polymers. 
 
3.2 HPLC METHOD 
The solubility of curcumin was quantified with a previously described HPLC 
quantification method (Hegge, A.B., et al., 2008). However, due to practical 
issues, one additional HPLC method was employed. The two methods are 
described below: 
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HPLC system I: system I consisted of a Waters Nova-Pak  C18, 3.9 x 150 
mm, 4µm particle size column by use of a Shimadzu Liquid Chromatography 
LC-9A pump, a Shimadzu Auto Injector SIL-10 AD auto sampler, a Shimadzu 
UV-Vis Spectrophotometric detector SPD-10A, and a Shimadzu C-R3A 
integrator. 
HPLC system II: system II consisted of a Waters Nova-Pak  C18, 3.9 x 150 
mm, 4µm particle size column by use of a Shimadzu Liquid Chromatography 
LC-20AD pump, a Shimadzu Auto Injector SIL-20AC HT auto sampler, a 
Shimadzu UV-Vis Spectrophotometric detector SPD-M20A, a CBM-20A 
controlling unit and a CTO-20A oven. 
 
3.2.1 Preparation of the buffers and the mobile phase 
0.026 M (0.5%) Citric acid buffer pH3: 
The citric acid buffer was prepared by dissolving a given amount of citric acid 
monohydride in a volumetric flask almost filled with purified water and 
adjusted to pH 3 +/- 0.1 by adding 10% (w/v) KOH solution. The pH was 
checked using a WTW pH 526 pH meter. Purified water was then added to 
the mark in the flask before filtration.  
The mobile phase was composed of 62 parts of MeOH to 38 parts of citric 
acid buffer for system I. 
 
Phosphate buffer pH 5 (0.05 M; ionic strength 0.085): 
The phosphate buffer was prepared by dissolving a given amount of the 
appropriate salt in purified water by using a volumetric flask. The ionic 
strength was fixed by adding a calculated amount of NaCl. The pH 5 +/- 0.2 
was checked using a WTW pH 526 pH meter. 
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The exact compositions of the buffer used in the phase solubility studies are 
presented in appendix A.3. 
 
3.2.2 Analytical conditions 
The retention time for curcumin was at around 12 minutes. 
All the quantitative analysis were done in triplicate to reduce random error. 
 
3.2.3 Curcumin quantification 
Linearity was investigated in the range 5x10-7 M and 1x10-5 M curcumin using 
a stock solution in methanol. Calibration of the instrument was performed 
with curcumin solutions in methanol (5x10-7 M, 1x10-6 M, 2x10-6 M and 1x10-5 
M) for quantification of curcumin. 
The quantification was performed using linear regression. The integrals were 
plotted on the x-axis and the concentration was plotted on the y-axis. This 
gave a straight line. The regression coefficient was > 0.99.  
 y = ax + b  
y is the concentration, x is the integral, a is the slope and b is the intercept.  
 
3.2.4 Phase solubility studies 
Phase solubility studies were performed by adding an excess amount of drug 
to several vials. A constant volume of solvent is added to each vial and also 
solvent containing successively larger concentrations of the complexing 
agent is then added. The vials are closed and the contents brought to 
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solubility equilibrium by shaking at a constant temperature. The suspensions 
are filtered and then analyzed for their total concentration of compound by 
HPLC.  
In the present study an excess amount of curcumin is added to different 
solvents containing increasing concentration 0.1, 0.3, 0.5, 1, 2, 3 and 5 % 
(w/v) of RMβCD.  
All investigations were performed at ambient temperature using three 
parallels. The samples were protected from light. 
7 different solvents were taken to compare their solubilizing effect under the 
given conditions with RMβCD.  
The samples were detected at the wavelength 420nm and 430nm. 
 
Table 2: this table shows the solvents, which were used. 
 
 
	  	   	  	  Solvent	  
crystalline	  
curcumin	  	  
	  Curcumin	  
in	  	  
ethanol	  
solution	  
(1x10-­‐3	  M)	  
	  
	  	  	   	  	  purified	  water	   x	   	  	  
	  	   	  	  purified	  water	  with	  1%	  (v/v)	  EtOH	  	   x	   	  	  
	  	  
	  	  0,1%	  (w/v)	  sodium	  alginate	  in	  	  	  
water	  +	  1%	  	  	  (v/v)	  EtOH	  	   x	   	  	  
	  	  RM-­‐β-­‐CD	  in	  different	  ratio	  	  
	  	  0,1%	  (w/v)	  HPMC	  in	  water	  +	  1%	  
(v/v)	  EtOH	  	   x	   	  	  
	  	   	  	  plain	  phosphate	  buffer	  (pH5)	   x	   	  	  
	  	  
	  	  phosphate	  buffer	  (pH5)	  +	  1%	  (v/v)	  	  	  	  	  	  
EtOH	  	   x	   	  	  
	  	   	  	  phosphate	  buffer	  (pH5)	  	   x	   x	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Determination of the water content in the cyclodextrin: 
It is important to determine the water content and correct it when preparing 
the cyclodextrin stock solution. The water content in the cyclodextrins was 
determined at the beginning of the studies of this thesis. 
The measurement was carried out by use of approximately 2g of the 
cyclodextrin. A Sartorius Moisture Analyzer, MA 30 was used. The 
cyclodextrin was dried at 130°C for 60 minutes, respectively. The samples 
were weighted on an analytical balance before and after measurement. The 
water content of the samples was calculated, based on the weight loss. As 
well, the measurements were done in triplicates, and the value used for 
concentration corrections was the average of the three parallels. 
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3.2.4.1 Phase-solubility-studies with purified water and purified 
water containing 1% (v/v) EtOH 
A 1% (w/v) cyclodextrin solution in water was prepared. The moisture content 
in the cyclodextrin was corrected for.  
Vials were filled with an excess amount of compound and an appropriate 
amount of the cyclodextrin solution was diluted according to the different 
concentrations in each vial. The concentrations were 0.1, 0.3, 0.5, 1, 2, 3 and 
5% (w/v) made from 1% stock solution of CD. The vials were sealed and 
were shaken for 1 day and protected from light. Undissolved curcumin was 
then removed by filtration 0.45 Spartan 13/0.45 RC before diluting the 
solution 1:1 with MeOH and analyzed by HPLC system I at 420nm 
wavelength to quantify the curcumin in the filtrate. The first drops of the 
filtrated samples were discarded. 
 
3.2.4.2 Phase-solubility-studies with plain phosphate buffer and 
phosphate buffer containing 1% (v/v) EtOH 
Three 1% (w/v) cyclodextrin solutions in phosphate buffer were prepared. 
The moisture content in the cyclodextrin was corrected for.  
One solution was prepared only with plain phosphate buffer and two 1% (w/v) 
cyclodextrin solutions in phosphate buffer containing 1% (v/v) EtOH were 
prepared differently. One study was investigated with crystalline and solved 
curcumin (100µl of curcumin in ethanol solution 1x10-3 M) and the other one 
was investigated simply with crystalline curcumin. 
Vials were filled with an excess amount of compound (and as well with 100µl 
of curcumin in ethanol solution). An appropriate amount of the cyclodextrin 
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solution was diluted according to the different concentrations in each vial. 
The concentrations were again 0.1, 0.3, 0.5, 1, 2, 3 and 5% (w/v) made from 
1% stock solution of CD. The vials were sealed and were shaken for 1 day 
and protected from light. Undissolved curcumin was then removed by 
filtration 0.45 Spartan 13/0.45 RC before diluting the solution 1:1 with MeOH 
and analyzed by HPLC system I at 420nm wavelength to quantify the 
curcumin in the filtrate. The first drops of the filtrated samples were 
discarded. 
 
3.2.4.3 Phase-solubility-studies with two different polymer in water 
containing 1% (v/v) EtOH 
Two 1% (w/v) cyclodextrin solutions with 2 different polymers in water were 
prepared. The moisture content in the cyclodextrin was corrected for.  
Vials were filled with an excess amount of compound and an appropriate 
amount of the cyclodextrin-polymer solution was diluted according to the 
different concentrations in each vial. The concentrations were 0.1, 0.3, 0.5, 1, 
2, 3 and 5% (w/v) made from 1% stock solution of CD. The vials were sealed 
and were shaken for 1 day and protected from light. Undissolved curcumin 
was then removed by filtration 0.45 Spartan 13/0.45 RC before diluting 1:1 
with MeOH and analyzed by HPLC system I at 420nm wavelength to quantify 
the curcumin in the filtrate. The first drops of the filtrated samples were 
discarded. 
 
3.2.4.4 Quantification of curcumin in the freeze-dried product – 
drug load 
An exact amount (approx. 0.005g) of the freeze dried product was added in 
1ml MeOH and immediately filtered with BD Plastipak 5ml sterile syringe 
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from Becton Dickinson S.A., fitted with Spartan 13/0.45 RC, 0.45µm filters 
from Whatman. The first drops of the filtrated samples were discarded. The 
samples were diluted 1:1 with MeOH before quantification by the previously 
described reversed phase HPLC method with the following modifications: 
HPLC system II was used, the flow rate was 0.8ml/min and the detection 
wavelength was 430nm for the quantification of curcumin. 
Degradation products were detected at different wavelength (350nm). 
 
3.3 ROTAVAPOR or THE SOLVENT EVAPORATION METHOD 
A homogenous drug-cyclodextrin system was prepared. Curcumin-
cyclodextrin complex was set up in the molar ratio of 1:1, 1:2 and 1:3 using 
methanol as solvent. The solvent (0.1g curcumin in 10ml MeOH; 0,2g 
curcumin in 10ml MeOH; 0.3g curcumin in 10ml MeOH) was then evaporated 
for ½ hour at 25°C in a Büchi EL – 131 rotavapor. The resulting product was 
a film, which was obtained after scraping the film in the glass vial and was 
stored over night in an exsiccator.  
The same procedure was repeated with curcumin in methanol (without CDs) 
as comparison. 
 
3.4 DSC 
A Mettler Toledo Stare System differential scanning calorimeter was used 
equipped with a DSC 822e Module.  
Samples of 1-1.5 mg of crystalline curcumin, pure CD, curcumin in methanol 
after evaporation, curcumin with CD in methanol after evaporation and of the 
freeze-dried products were heated in an aluminum pan, an aluminum top was 
placed on the sample and crimped in place, under static atmosphere. An 
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empty pan was used as reference. The heating rate was 10°C/min and the 
temperature interval used was 5°C to 220°C, under a constant flow 
(100ml/min) of nitrogen gas. The equipment was calibrated with indium. 
 
3.5 LYOPHILIZATION 
Lyophilization is a very complex process (Patil, V.V., et al., 2010).  
For Lyophilization Virtis 25ES from Virtis Company Inc. USA was used. A 
vacuum pump, named Leybold, Trivac D16B from Engineering Company 
Inc., USA was used. 
An excess of cyclodextrin:curcumin powder (from the solvent evaporation) 
was dissolved in 10ml purified water by shaking (approximately 3min) and if 
necessary with the help of an ultrasonic bath (sonication). It was filtered with 
0.45 Spartan 13/0.45 RC. After filtration 0.01g HPMC was dissolved in the 
filtrate. HPMC was chosen to carry out the following studies by lyophilization 
because the increased viscosity of sodium alginate complicated the filtration 
of the solutions prior to freeze dry and prior to quantification. 
The vials were freeze-dried according to the following procedure: 
Samples (approximately 10ml of the sample in 50ml glass vials with open 
plastic stopper) were put on the shelves and were frozen at -48°C for 24 
hours. Meanwhile, the temperature of the condenser of the freeze dryer was 
allowed to reach at its minimum level of -50°C. Thereafter, the frozen 
samples are still placed in the drying chamber and then the vacuum pump 
and the heater were switched on. Vacuum was applied, and the samples 
were subjected to lyophilization for 72 hours in the freeze dryer.  
Before initiating the second drying step and increasing the temperature for it, 
the vacuum should be below 100mbar first. If these conditions are 
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accomplished, the secondary drying step with 10°C for 2 hours, 20°C for 1 
hour and 40°C for 2 hours was succeeded. 
Finally, the vials were closed by pressing the plastic stopper. 
 
3.6 SEM 
The surface morphology of pure curcumin, pure RM-β-cyclodextrin, 
curcumin:cyclodextrin product after solvent evaporation and the freeze-dried 
product was investigated using a Hitachi S-4800 scanning electron 
microscope from Hitachi High-Technologies, Canada. The samples were 
spread on a brass stub using double-sided tape and then sputtered with a 
thin layer of gold platinum. The pictures were taken at an acceleration 
voltage of 1 kV. 
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4 RESULTS AND DISCUSSION 
 
4.1 CURCUMIN COMPLEXATION WITH RMβCD 
4.1.1 Phase solubility studies – the effect of solvents  
Phase solubility studies were carried out according to the method described 
by Higuchi and Connors (1965). 
Phase solubility studies were performed in different solvents to investigate if 
the medium affected the curcumin-cyclodextrin complexation. 
Because of the symmetric appearance of curcumin with two identical 
aromatic rings, it is a possibility that both 1:1 guest-host inclusion complexes 
and 1:2 guest-host inclusion complexes can be formed with cyclodextrins. As 
seen in figure 6, 1:1 stoichiometry includes one aromatic moiety in the 
cyclodextrin cavity, 1:2 stoichiometry includes both aromatic moieties into the 
cyclodextrin cavities of two different cyclodextrin molecules (Singh, R., et al., 
2010). 
 
 
Figure 6: curcumin-cyclodextrin complexation (Singh, R., et al., 2010) 
 
In the present study, non-linear, Ap-like curves for curcumin with RMβCD in 
water with and without ethanol were obtained (figure 7).  
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Figure 7 : Phase solubility diagram of curcumin in purified water showing Ap like curves.  
The curves show the solubility of curcumin at increasing concentrations (w/v) of RMβCD in purified water and 
purified water containing 1% (v/v) ethanol 
 
RMβCD	  concentration	   	  	   	  	   	  	   	  	  
	  	  
curcumin	  
concentration	  
(M)	  
in	  purified	  water	   	  +/-­‐	  SD	  
Curcumin	  concentration	  
(M)	  in	  purified	  water	  
+	  1%	  (v/v)	  EtOH	  	   	  +/-­‐	  SD	  
0,10%	   5.11x10-­‐7	   9.34x10-­‐8	   3.43x10-­‐7	   1.06x10-­‐7	  
0,30%	   1.66x10-­‐6	   3.51x10-­‐7	   1.85x10-­‐6	   7.20x10-­‐7	  
0,50%	   3.10x10-­‐6	   2.00x10-­‐7	   4.02x10-­‐6	   7.07x10-­‐7	  
1%	   6.55x10-­‐6	   4.76x10-­‐7	   9.81x10-­‐6	   8.89x10-­‐7	  
2%	   2.54x10-­‐5	   1.86x10-­‐6	   2.84x10-­‐5	   1.33x10-­‐6	  
3%	   5.84x10-­‐5	   1.02x10-­‐6	   5.98x10-­‐5	   1.08x10-­‐6	  
5%	   1.24x10-­‐4	   2.39x10-­‐6	   1.66x10-­‐4	   6.13x10-­‐6	  
 
Table 3: The concentration of curcumin (M) expressed as the calculated mean +/- SD in different concentration 
(w/v) of RMβCD solution in purified water and purified water containing 1% (v/v) ethanol 
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An Ap-like curve suggests the formation of higher order complexes (Loftsson 
et al., 2004b). The curves appear similar at low concentrations of CDs, 
however, at a higher cyclodextrin concentration curcumin is more soluble in 
water containing 1% (v/v) ethanol (figure 7).  
The highest solubility of curcumin obtained in the present study was 1.66x 
10-4 M as detected in 5% (w/v) RMβCD in purified water containing 1% (v/v) 
ethanol. In general, increased concentrations of cyclodextrin corresponde to 
increased solubility of curcumin, that is, if the inclusion complex is formed, 
sufficiently soluble in water. 
Several papers have been published on the complexation of curcumin with 
cyclodextrins. 
Tønnesen, H.H., et al., 2002a reported an increase in water solubility at pH 5 
by a factor of at least 104, resulting from complex formation of curcumin and 
cyclodextrin. The highest concentration obtained in this study was 8x10-4 M 
of curcumin, measured in 11% solution of RM-β-cyclodextrin (Tønnesen, 
H.H., et al., 2002a).  
Hegge, A.B., et al., 2009 reported a decrease in complexation and as well 
the overall solubility decreases in presence of ethanol in previously 
performed phase-solubility-studies with curcumin and HPβCD. These studies 
were obtained in phosphate buffer (pH 5) with 10% ethanol or in plain buffer. 
It might be that ethanol, being a small molecule, stabilizes the formations of 
higher order complexes, in particular 1:2 guest-host complexation (curcumin : 
CD). 
Tang et al., 2002, as well, reported an 1:2 (guest:host) complex with βCD 
using spectrophotometric investigations. 
The results of these previous studies of curcumin in CD solutions show that 
the complexing medium affected the stoichiometry of the curcumin-
cyclodextrin complexation. 
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Figure 8 shows two Ap-like curves for curcumin with RMβCD in formulations 
with phosphate buffer containing 1% (v/v) ethanol and in plain phosphate 
buffer. The Ap-type of diagram of phosphate buffer containing 1% (v/v) 
ethanol was consistent with 2:1 or 3:1 complex formation between RMβCD 
and curcumin. As mentioned before, the formation of higher order complexes 
is suggested with an Ap-type of diagram, as well as with the symmetrical 
molecule appearance of curcumin with its two phenyl moieties. Both moieties 
are able to suit into the cyclodextrin cavity on each end (Loftsson, T., et al., 
2004b; Hegge, A.B., et al., 2009). 
In 11% (w/v) solution of RMβCD, the highest concentration, approximately 
8x10-4 M of curcumin was measured in phosphate buffer by Tønnesen, H.H., 
et al. (Tønnesen, H.H., et al., 2002a). 
 
 
Figure 8: Phase solubility diagram of curcumin in phosphate buffer showing Ap like curves.  
The curves show the solubility of curcumin at increasing concentrations (w/v) of RMβCD with different solvents 
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RMβCD	  concentration	   	  	   	  	   	  	   	  	  
	  	  
curcumin	  
concentration	  (M)	  	  
	  in	  plain	  buffer	   	  +/-­‐	  SD	  
curcumin	  
concentration	  (M)	  
in	  phosphate	  buffer	  
containing	  1%	  (v/v)	  
EtOH	   	  +/-­‐	  SD	  
0,10%	   7.57x10-­‐7	   1.49x10-­‐7	   4.28x10-­‐7	   1.45x10-­‐7	  
0,30%	   2.21x10-­‐6	   3.48x10-­‐7	   1.75x10-­‐6	   4.54x10-­‐7	  
0,50%	   4.51x10-­‐6	   5.29x10-­‐7	   4.12x10-­‐6	   1.98x10-­‐7	  
1%	   9.65x10-­‐6	   6.17x10-­‐7	   8.57x10-­‐6	   1.11x10-­‐6	  
2%	   3.06x10-­‐5	   3.55x10-­‐7	   2.41x10-­‐5	   1.45x10-­‐6	  
3%	   6.67x10-­‐5	   6.93x10-­‐6	   5.52x10-­‐5	   2.48x10-­‐6	  
5%	   1.61x10-­‐4	   8.24x10-­‐6	   1.77x10-­‐4	   6.21x10-­‐6	  
 
Table 4: The concentration of curcumin (M) expressed as the calculated mean +/- SD in different concentration 
(w/v) of RMβCD solution in plain phosphate buffer and phosphate buffer containing 1% (v/v) ethanol 
 
Previous investigations with another beta derivative i.e. HPβCD observed on 
curcumin-CD complexation showed 2:1 host-guest inclusion complex in 
distilled water (Baglole et al., 2005) and a 1:1 host-guest inclusion complex in 
phosphate buffer (Tønnesen, H.H., et al., 2002b). Hegge, A.B., et al., 2008 
observations with phosphate buffer (µ=0.085) : ethanol (9:1) indicated mainly 
1:1 stoichiometry. The phase solubility diagram of curcumin in a solution of 
HPβCD is close to linear and its slope is less than one, which indicates a 1:1 
stoichiometry. But also a formation of higher order complexes is possible. 
The phase solubility diagram obtained in HPβCD/phosphate buffer without 
ethanol showed an Ap-like curve, which indicates higher order of 
complexation between the host and the guest molecule. 
Hegge, A.B, et al., 2009 did again investigations with HPβCD and showed 
mainly 1:1 stoichiometry but also higher order complexes can’t be eliminated. 
This study was investigated with the same solvent and the same synthesized 
curcumin but with a UV-VIS titration method. Due to different methods 
(Stoichiometry studies performed with HPLC can’t be easily compared with 
UV-VIS titration method) a possibility of different reported curcumin-
cyclodextrin stoichiometries could occur (Hegge, A.B., et al., 2009).  
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Figures 7 and 8 show non-linear Ap-type of phase solubility diagrams for both 
in the presence and absence of ethanol. In both systems the presence of 
ethanol enhances the overall solubilizing effect of CD. More precisely, in the 
presence of ethanol, the distinction in solubility is higher within the 
investigation with purified water than within the investigations with phosphate 
buffer. In fact, 1% (v/v) ethanol affects the complexation in both systems, in 
purified water and phosphate buffer. Compared to the investigations Hegge, 
A.B., et al., 2008 have performed on HPβCD. Here, in both systems 
(phosphate buffer and as well phosphate buffer with ethanol 9:1), the 
presence of ethanol decreases the overall solubiliizing effect of CD (Hegge, 
A.B., et al., 2008). In this particular case the effect of ethanol may be caused 
by a competitive binding i.e. ethanol is able to displace curcumin in the 
cyclodextrin cavity (Loftsson, T., et al.1999; Hegge, A.B., et al., 2008). 
 
The phase solubility-curves obtained in Figure 9, when curcumin was added 
as a combination of crystalline curcumin (approximately 8mg) and of 
curcumin dissolved in ethanol (10-3 M) were compared to phase solubility 
curves showed in Figure 8. At CD concentration ≤ 2% the apparent solubility 
of curcumin is higher compared to the solubility detected, when only 
crystalline curcumin is added to the same solvent. The total concentration of 
ethanol in the phosphate buffer is 1% (v/v) EtOH. The increased solubility of 
curcumin observed in Figure 9 might be caused by curcumin in a 
supersaturated state. CDs are reported to be able to delay crystallization of 
drugs from supersaturated solutions (Brouwers, J., et al., 2009).  
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Figure 9: The diagram shows the solubility of curcumin at increasing concentrations (w/v) of RMβCD with different 
solvents 
 
RMβCD	  concentration	   	  	   	  	   	  	   	  	  
	  	  
curcumin	  
concentration	  (M)	  of	  
crystalline	  +	  solved	  
curcumin	  in	  
phosphate	  buffer	  I	   	  +/-­‐	  SD	  
curcumin	  
concentration	  (M)	  
of	  crystalline	  +	  
solved	  curcumin	  in	  
phosphate	  buffer	  II	   	  +/-­‐	  SD	  
0,10%	   1.20x10-­‐6	   4.21x10-­‐7	   1.69x10-­‐6	   5.89x10-­‐7	  
0,30%	   9.65x10-­‐6	   6.31x10-­‐7	   8.63x10-­‐6	   1.29x10-­‐6	  
0,50%	   2.36x10-­‐5	   2.15x10-­‐6	   1.97x10-­‐5	   1.60x10-­‐6	  
1%	   4.76x10-­‐5	   1.61x10-­‐6	   3.65x10-­‐5	   8.89x10-­‐7	  
2%	   5.45x10-­‐5	   1.42x10-­‐6	   4.17x10-­‐5	   5.80x10-­‐6	  
3%	   6.90x10-­‐5	   4.17x10-­‐6	   5.09x10-­‐5	   6.19x10-­‐6	  
5%	   1.45x10-­‐4	   1.10x10-­‐5	   1.36x10-­‐4	   2.92x10-­‐5	  
 
 
Table 5: Molar solubility of curcumin in different concentration (w/v) of RMβCD solution investigated with phosphate 
buffer.  
The total concentration of ethanol is 1% (v/v) for all the samples. The concentration of curcumin (M) is expressed as 
well as the calculated mean +/- SD. 
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Thus, cyclodextrins can potentially stabilize a supersaturated state at low CD 
concentration. By adding dissolved curcumin and shaking the samples for 
one day a supersaturated system could occur. However, the supersaturated 
system may return to equilibrium if the shaking time would be enhanced to 1 
week, for example. Further, investigations will be needed to clarify this. 
 
The effect of small amounts of alginate and HPMC on the curcumin: 
cyclodextrin complexation was investigated. Ap-like curves indicating higher 
order complexation (Figure 8) were obtained in water containing 1% (v/v) 
ethanol. Compared to other investigations at same conditions but without 
polymers, alginate did not increase the complexation, however, HPMC 
appeared to decrease the complexation. 9.69x10-5 was the highest curcumin 
concentration as detected in 5% (w/v) RMβCD in HPMC in water containing 
1% (v/v) EtOH compared to the highest curcumin concentration of 1.65x10-4 
as detected in 5% (w/v) RMβCD in sodium alginate in water containing 1% 
(v/v) EtOH. Neither the presence nor the type of polymer did change the 
complexing abilities between curcumin and CD with 1% (v/v) ethanol in the 
complexing medium. 
Loftsson, T. (Loftsson, T., et al., 1998) investigated the effect of complex 
formation between drug und β-cyclodextrin contained CMC, PVP or HPMC 
on the solubility. Adding different types of polymer resulted in a 3-10% 
increase in the total aqueous solubility of βCD but the drug–βCD 
complexation results in a 40% to >100% increase in solubility. The aqueous 
solubility of βCD is increased and it is caused by the polymers but its ability 
to form inclusion complexes isn’t decreasing. In most cases, the polymers 
increase the complexing abilities of βCD (Loftsson, T., et al., 1998).  
Hegge, A.B., et al., 2009 showed that the presence of various co-solvents, 
e.g. 0.1% (w/v) sodium alginate or propylene glycol alginate, did not affect 
the stoichiometry of the complexes formed. Neither the presence nor the type 
of alginate did change the complexation between curcumin and CD with 10% 
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(v/v) ethanol in the complexing medium. In the case of HPβCD a 30-90% 
increase in the association constant was observed in the presence of 
alginates (Hegge, A.B., et al., 2008). 
 
Figure 10: Phase solubility diagram of curcumin with different types of polymer showing Ap like curves.  
The curves show the solubility of curcumin at increasing concentrations (w/v) of RMβCD in purified water containing 
1% (v/v) EtOH and/ or containing different types of polymer  
 
RMβCD	  
concentration	  	  	   	  	   	  	   	  	  
	  	  
curcumin	  
concentration	  (M)	  in	  
0.1%	  (w/v)	  HPMC	  in	  
water	  	  
+	  1%	  (v/v)	  EtOH	   	  +/-­‐	  SD	  
curcumin	  
concentration	  (M)	  in	  
0.1%	  (w/v)	  alginate	  
in	  water	  	  
+	  1%	  (v/v)	  EtOH	   	  +/-­‐	  SD	  
0,10%	   2.79x10-­‐7	   5.79x10-­‐8	   3.43x10-­‐7	   7.33x10-­‐8	  
0,30%	   7.89x10-­‐7	   6.80x10-­‐7	   1.15x10-­‐6	   4.64x10-­‐7	  
0,50%	   2.20x10-­‐6	   6.90x10-­‐7	   2.14x10-­‐6	   1.07x10-­‐6	  
1%	   5.90x10-­‐6	   2.29x10-­‐6	   7.04x10-­‐6	   8.98x10-­‐7	  
2%	   1.40x10-­‐5	   5.70x10-­‐6	   1.89x10-­‐5	   5.36x10-­‐6	  
3%	   3.65x10-­‐5	   3.09x10-­‐6	   6.19x10-­‐5	   3.44x10-­‐6	  
5%	   9.69x10-­‐5	   3.54x10-­‐6	   1.65x10-­‐4	   6.41x10-­‐6	  
 
Table 6: The concentration of curcumin (M) expressed as the calculated mean +- SD in different concentration (w/v) 
of RMβCD solution with 2 different polymers in purified water containing 1% (v/v) ethanol 
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4.1.2 Quantification of curcumin after freeze-drying – drug load 
As seen in table 7, the averages of the curcumin load in the freeze-dried 
product obtained from four different runs of freeze drying. There is a clear 
variation between the different runs. It is caused by different reasons. One of 
the reasons is that the dissolution rate of the product after solvent 
evaporation wasn’t controlled, which is an important factor to observe in the 
future. But also the freeze-dried process needs better technical preparation in 
the future.  
	  	  
average	  
curcumin	  
load	  of	  the	  
1:1	  product	  	   +/-­‐	  SD	  
average	  
curcumin	  
load	  of	  the	  
2:1	  product	  	   +/-­‐	  SD	  
average	  
curcumin	  
load	  of	  the	  
3:1	  product	  	   +/-­‐	  SD	  
	  	   	   	  	   	   	  	   	  	   	  	  
1	  run	   0,0745%	   0,0068%	   0,2273%	   0,0120%	   0,2629%	   0,0090%	  
2	  run	   0,1216%	   0,0040%	   0,1695%	   0,0044%	   0,3064%	   0,0098%	  
3	  run	   0,0892%	   0,0032%	   0,2079%	   0,0070%	   0,2665%	   0,0173%	  
4	  run	   0,2500%	   0,0156%	   0,2483%	   0,0127%	   0,3869%	   0,0698%	  
 
Table 7: Curcumin load in % after freeze-drying 
The average of the curcumin load of the freeze dried products in the ratio 1:1, 2:1, 3:1 (CD:curcumin), respectively, 
which were used to prepare the solution for the solvent evaporation 
 
Ratio	  of	  CD:Cur	  in	  %	  (w/w),	  
which	  was	  used	  to	  prepare	  the	  
solution	  for	  the	  solvent	  
evaporation	  for	  the	  freeze	  drying	  
step	  
average	  curcumin	  load	  in	  %	  (w/w)	  of	  
the	  freeze	  dried	  products	   +/-­‐	  	  S.D	  
	  	   	  	   	  	  
1:1	   0,1338%	   0,0057%	  
2:1	   0,2133%	   0,0040%	  
3:1	   0,3057%	   0,0291%	  
 
Table 8: The average (of 4 runs) of the detected curcumin load and +/- standard deviation (SD) after freeze-drying 
 
In Table 8 the averages of all the common products are summarized. Also 
the standard deviation is indicated. This table shows that the selected ratio of 
CD:curcumin influences the final drug load of the freeze dried product. A 3:1 
(CD:Cur) resulted in the highest drug load detected of 0.31% (w/w) curcumin. 
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Hegge, A.B., et al., 2010 reported a theoretical curcumin load of 0.15% (w/w) 
in previous prepared alginate foams. Different ratios between CDs and 
curcumin were selected to investigate the effect of the CDs on the physical 
characteristics of the foams, the curcumin release and photostability (Hegge, 
A.B., et al., 2010). 
The optimal ratio of CD:curumin needs to be established. The importance of 
selection the optimal ratio of CD:curcumin to obtain the most efficient 
complexation in the solvent evaporation has been demonstrated in case of 
curcumin and HPγCD (Singh, R., et al., in process). As well more importantly 
is the question, how it is possible to reach the highest possible curcumin load 
from the solvent evaporation product before freeze drying. However, in order 
to find the optimal ratio of MβCD:curcumin, further studies will be needed. It 
is essential to control the solubility of curcumin in the solution used for the 
freeze-dried process in order to control the drug load of the final product.  
 
4.1.3 Degradation of the products after freeze-drying 
The HPLC chromatograms indicate some degradation of curcumin, observed 
as several unidentified peaks. In Figure 11 only curcumin appears at 430nm 
and compared to the other figure 12 at a wavelength 376nm there are 
several unidentified peaks, which are not visible at 430nm. These 
unidentified peaks with retention time less than 4 min can be caused by 
impurities in the synthesized curcumin powder. In this thesis an excess of 
powder was used and it was filtered before freeze drying. Accordingly 
impurities might be visible in the HPLC chromatogram. Further investigations 
need to be done if these unidentified peaks are caused by degradation of 
curcumin or by impurities of the starting compound. 
Feruloylmethane, ferulic acid, vanillin and also condensation products of 
feruloylmethane are some of the degradation products of curcumin, as 
already mentioned in 2.1.3.3 (Tønnesen, H.H., Karlsen, J., 1985a).  
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Figure 11: HPLC chromatogram of the product after freeze-drying at the wavelength 430nm 
 
 
Figure 12: HPLC chromatogram of the product after freeze–drying at the wavelength 367nm 
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4.2 ROTAVAPOR 
Two different systems were utilized. First system was curcumin dissolved in 
methanol. Second system was the combination of curcumin-cyclodextrin in 
methanol. Both systems were evaporated by a rotavapor. After evaporation 
both samples had the same powder-like visual appearance. Analyzed by 
DSC and SEM there are differences, which are mentioned in the section 
below. 
 
4.3 DSC and SEM 
Differential scanning calorimetry is a fast and relatively inexpensive 
technique to characterize the physical state of drugs or complexes of drugs 
(Bing, M., et al., 2010). DSC measures the energy change, which is the heat 
flow. 
Scanning electron microscopy was used to imagine the sample surface by 
scanning it with high-energy beam of electrons in a raster scan pattern 
(Wikipedia, 2010).  
DSC and SEM pictures of crystalline curcumin, pure RMβCD, curcumin with 
RMβCD in MeOH after evaporation and the freeze-dried product are shown 
in Figures 13-27. The SEM pictures below show the various components in 
their different appearance. 
 
4.3.1 DSC and SEM of crystalline curcumin 
The thermograms of pure curcumin in figure 13 show an intense melting 
endotherm at around 180°C corresponding to the melting point of pure 
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curcumin, which is specified in literature (Merck, 2001). In addition to this, a 
heating-cooling-heating cycle in exact temperatures from 25°C to 200°C back 
to 25°C and from 25°C to 300°C with the heating rate of 10°C/min was 
operated. This showed that curcumin doesn’t recrystallize by cooling 
because exothermal crystallization could not be observed. It remains 
amorphous. By reheating it undergoes glass transition at around 70°C. This 
glass transition is indicated with the red box in figure 13. 
 
 
Figure 13: DSC thermograms of pure curcumin.  
The blue and green curves show the heating-cooling-heating cycle. The red box indicates the glass transition. 
 
Figures 14 and 15 show two SEM pictures of pure curcumin with different 
magnification. Overall, it can be observed that curcumin appears as 
crystalline needles. 
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Figure 14: SEM picture of pure curcumin with a magnification of 200. 
 
 
Figure 15: SEM picture of pure curcumin with a magnification of 900 
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4.3.2 DSC and SEM of RMβCD 
The previous detected water content in RMβCD was 2.8%. The first 
endothermic peak in pure RMβCD in figure 16 is evaporation of residual 
water. Compared to pure curcumin, pure RMβCD undergoes glass transition 
at around 170°C which is again indicated with the red box. A heating-cooling-
heating cycle was performed, which is seen in figure 17. The first heating 
from 25-110°C showed again evaporation of residual water which results in 
an endothermic peak. During the second heating from 25-220°C a glass 
transition at around 170°C appeared. In the producers technical sheet it is 
mentioned that the melting point of RMβCD is in the range of 165-172°C but 
according to another reference this selected cyclodextrin should be 
noncrystalline, which occurs in glass transition but in no melting (Froemming, 
K-H., et al. 1994).  
The analyses in this present study show an amorphous state of the 
randomized-methylated-β-cyclodextrin due to the absences of a melting peak 
and the observer glass transition at around 170°C (figures 16 and 17). 
 
Figure 16: DSC thermograms of pure curcumin with its intense endothermic peak and pure RMβCD with its glass 
transition.  
The red box indicates the glass transition. 
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Figure 17: DSC thermograms of pure RMβCD and also its heating-cooling-heating cycle in the colors blue, green 
and violet.  
The red box indicates the glass transition. 
 
 
SEM pictures of pure RMβCD with different magnifications are shown in 
figures 18 and 19. With the results from DSC and the analyses with SEM it 
seems that this selected cyclodextrin is amorphous. 
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Figure 18: SEM picture of pure RMβCD with a magnification of 200 
 
 
Figure 19: SEM picture of pure RMβCD with a magnification of 2000 
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4.3.3 DSC and SEM of cur : CD product after solvent evaporation 
A solution of curcumin and cyclodextrins in methanol was prepared and the 
solvent was removed by solvent evaporation using a rotavapor. Analyses of 
the resulting product are shown in figure 20. The absence of an endothermic 
peak indicates that the product is not crystalline anymore but amorphous. 
The DSC thermograms of curcumin + cyclodextrin in MeOH after evaporation 
(violet trace) show an endothermic peak in the beginning and as well glass 
transition occurred comparable to the pure β-cyclodextrin (red trace). A 
heating-cooling-heating cycle was operated, which shows glass transition at 
around 140°C during the second heating from 5-220°C. This indicates that 
curcumin with cyclodextrin after evaporation is turned amorphous compared 
to pure curcumin before evaporation, which has a melting point and is 
consequently crystalline. 
 
 
Figure 20: DSC traces of pure curcumin (black trace) and pure RMβCD (red trace) in comparison to curcumin + 
cyclodextrin in MeOH after evaporation (violet trace).  
The red box indicates the glass transition. 
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The SEM pictures demonstrate that curcumin with RMβCD in MeOH after 
evaporation have a flake-like structure throughout the sample as it is shown 
in figure 21 with a magnification of 150 and in figure 22 with a magnification 
of 6000. However, the prior morphology of the parent compounds 
disappeared and it is impossible to differentiate between the two initial 
components. A totally new appearance occurred. 
 
 
Figure 21: SEM picture of curcumin with RMβCD in MeOH with a magnification of 150 
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Figure 22: SEM picture of curcumin with RMβCD in MeOH with a magnification of 6000 
 
The pure curcumin in methanol after evaporation was analysed as a control. 
Analyzing the product after evaporation by DSC with the heating rate of 
10°C/min in the range of 5-220°C the same intense endothermic peak 
appears at around 180°C as seen in pure curcumin powder, which indicates 
the crystalline form of curcumin again (figure 23). The absence of a glass 
transition approves that curcumin in MeOH after evaporation is still 
crystalline, compared to the thermogram in figure 20 (with cyclodextrins), 
where glass transition appears at around 140°C, which indicates an 
amorphous structure. 
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Figure 23: DSC thermograms of pure curcumin and the curcumin in methanol after evaporation 
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4.3.4 DSC of the freeze-dried products 
The thermograms of three freeze-dried products with different CD:Cur ratios 
in figure 24 are similar in appearance. During heating from 5-220°C with the 
heating rate of 10°C/min glass transition appears in the range of 60-80°C. No 
melting endotherm was observed at around 180-190°C where pure curcumin 
is supposed to has its melting point. Consequently crystalline curcumin was 
not detected in the freeze-dried product. 
 
 
Figure 24: DSC thermograms of freeze-dried products with different ratios.  
Violet trace - CD:Cur ratio 1:1, green trace - CD:Cur ratio 2:1, black trace - CD:Cur ratio 3:1 
 
Figure 25, 26 and 27 show the freeze-dried curcumin/ RMβCD/ HPMC 
system with its polymer structure with different magnification (45, 80 and 
2200). The prior morphology of the parent compounds disappeared and a 
totally new appearance occurred. Ice crystals formed during the freezing 
process left behind the large pores.  
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Figure 25: SEM picture of the freeze-dried curcumin/ RMβCD/ HPMC system with a magnification of 45 
 
 
Figure 26: SEM picture of the freeze-dried curcumin/ RMβCD/ HPMC system with a magnification of 80 
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Figure 27: SEM picture of the freeze-dried curcumin/ RMβCD/ HPMC system with a magnification of 2200 
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4.4 LYOPHILIZATION 
In order to improve the physical and chemical stability of the samples and to 
convert solutions or suspensions into solids, one of the most commonly used 
processes is freeze-drying (Patil, V.V., et al., 2010).  
All freeze-dried products had a sponge like morphology. After lyophilization 
the products appeared like foam. Figure 28 shows a representative freeze-
dried sample containing curcumin, CD and HPMC in a typical freeze-dried 
vial with plastic stopper. 
 
 
Figure 28: one of the freeze-dried sample in a freeze-dried vial with plastic stopper 
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5 SUMMARY AND CONCLUSION 
 
Curcumin has a wide range of pharmacological properties and is currently 
under intense investigation as a possible photosensitizer in a PDT. However, 
the extremely low aqueous solubility of curcumin and low stability at 
physiological conditions, solubilization and protection from degradation will 
be necessary in order to utilize this compound as a drug.  
The aim of this master thesis was to improve the solubility and dissolution 
rate of curcumin by using a selected cyclodextrin. With the aid of phase 
solubility studies conducted by Higuchi and Connors (1965), the solubility of 
curcumin in 7 different solvents was investigated. All these studies show non-
linear, Ap-like curves independent from the solvent used. This indicates some 
kind of higher order complexation.  
As described in chapter 4.1 the highest curcumin concentration obtained in 
the present study was 1.77x10-4 M as detected in 5% (w/v) RMβCD in 
phosphate buffer containing 1% (v/v) ethanol. Similar solubilities were 
detected independent of the solvent used and independent of the presence 
of 0.1% alginate. There is no increasing solubility by adding any polymer. In 
fact, less solubility occurred by adding HPMC.  
Different solubility curves were found when curcumin was added as a 
combination of curcumin dissolved in EtOH (10-3) together with crystalline 
curcumin to RMβCD in phosphate buffer. In the beginning the curves 
seemed to be linear but at higher cyclodextrin concentration the curves 
started being Ap-like. At CD concentration ≤ 2% the apparent solubility of 
curcumin is higher compared to the solubility detected, when only crystalline 
curcumin is added to the same solvent. The increased solubility of curcumin 
might be caused by curcumin in a supersaturated state, which cyclodextrins 
54	  
	  
potentially stabilize. Further investigations under different buffer conditions 
will be needed to clarify this. 
To further enhance the solubility of curcumin in aqueous solutions, a solvent 
evaporation method was selected. In fact, the product of curcumin with 
cyclodextrin after evaporation is turned amorphous compared to the pure 
curcumin before evaporation, which is crystalline. The prior morphology of 
the parent compounds disappeared after solvent evaporation and a totally 
new product appeared. 
The figure below shows the series of tests, which were performed in this 
study to find the most promising product to enhance the solubility and 
stability of curcumin. Even though 0.1% (w/v) HPMC in water with 1% (v/v) 
EtOH didn’t get as promising solubilizing effect as sodium alginate, HPMC 
was chosen to carry out the following studies. The increased viscosity of 
sodium alginate complicated the filtration of the solutions prior to freeze dry 
and prior to quantification. 
 
 
 
55	  
	  
The method of lyophilization was used to improve the physical and chemical 
stability of this new product. But at this point the procedure of lyophilization 
with a curcumin/ cyclodextrin/ HPMC solution is in its infancy. To find out the 
best conditions, a lot of measurements need to be taken.  
Nonetheless, some analyses of the lyophilized products were performed but 
the products haven’t been fully characterized yet.  
By checking the freeze-dried products with DSC, a glass transition occurred, 
which indicates that the product after lyophilization remains amorphous.  
The drug load of the freeze-dried products shows great promise as well. 
0.31% (w/w) curcumin load was detected in 3:1 CD:Cur ratio. Unfortunately 
it’s a clear variation between the different runs. It is caused by different 
reasons. It is essential to control the solubility of curcumin in the solution 
used for the freeze-dried process in order to control the drug load of the final 
product. Also the lyophilization process needs better technical preparation in 
the future.  
The specific degradation products haven’t been investigated so far. The 
HPLC chromatograms indicate some degradation of curcumin, observed as 
several unidentified peaks. Further investigations need to be done if these 
unidentified peaks are caused by degradation of curcumin or by impurities of 
the starting compound.  
Furthermore, to find the exact water content of the lyophilized product, a 
Fischer titration could be carried out in the future. 
However, a porous freeze-dried product will probably increase the dissolution 
rate and solubility of curcumin markedly. After all it will still be able to protect 
curcumin from degradation during storage. Such product has a potential use 
as a topical drug delivery system. This interesting and promising project has 
just started. More investigations need to be conducted in the future. 
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Appendix: 
A.1 Equipment 
 
HPLCs: 
HPLC system I: system I consisted of a Waters Nova-Pak  C18, 3.9 x 150 
mm, 4µm particle size column by use of a Shimadzu Liquid Chromatography 
LC-9A pump, a Shimadzu Auto Injector SIL-10 AD auto sampler, a Shimadzu 
UV-Vis Spectrophotometric detector SPD-10A, and a Shimadzu C-R3A 
integrator. 
HPLC system II: system II consisted of a Waters Nova-Pak  C18, 3.9 x 150 
mm, 4µm particle size column by use of a Shimadzu Liquid Chromatography 
LC-20AD pump, a Shimadzu Auto Injector SIL-20AC HT auto sampler, a 
Shimadzu UV-Vis Spectrophotometric detector SPD-M20A, a CBM-20A 
controlling unit and a CTO-20A oven. 
 
Rotavapor:  Büchi EL -131 
Differential scanning calorimeter:  Mettler Toledo Stare System 
DSC822e and Mettler Doledo STARe software 
 
Lyophilization:  Virtis 25ES from Virtis Company Inc. USA.  
Vacuum pump: Leybold, Trivac D16B from Engineering Company Inc., USA 
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Scanning electron microscope:  Hitachi S-4800 scanning electron 
microscope 
Moisture analyzer: Sartorius Moisture Analyzer MA30 
Analytical weight: Sartorius analytical weight 
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A.2 Reagents 
Chemical Lot Number Supplier 
Citric Acid monohydride 08D150022 VWR International 
Kaliumhydroxid 11293 Eka Nobel AB/ Nobel Industrier 
Natriumchlorid 9D122/4 Norsk Medisinaldepot, Norway 
Methanol Chromasolv® (HPLC-grade) SZBA1195 Sigma-Aldrich Co./Chemie GmbH 
Ethanol  Norsk Medisinaldepot, Norway 
Natriumhydrogenphosphatdihydrat K91380845 819 Merck KGaA 
Di-natriumhydrogenphosphatdihydrat K27618980 020 Merck KGaA 
RM- β-cyclodextrin = Cavasol W7 M 71T051 Wacker Chemie AG 
Hydroxypropylmethylcellulose 8028204 Shin-Etr Chemie. Lv. 
Sodium Alginate (Protanal® LF 10/60 LS)   S17261 FMC BioPolymers/NovaMatrix 
 
A.3 Buffers and mobile phase 
A.3.1 Buffer for HPLC (mobile phase) 
0.026 M (0.5%) Citrate buffer pH 3:  
For 1000ml buffer: 
5.47 g citric acid anhydrate 
pH adjusted to 3 with 10% KOH solution 
 
A.3.2 Buffer for phase solubility experiments 
Buffer: phosphate buffer pH 5 (0.05 M; ionic strength 0.085): 
For 1000ml buffer: 
7.8 g NaH2PO4 x 2 H2O 
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0.089 g Na2HPO4 x 2 H2O 
2g NaCl 
 
A.3.3 Mobile Phase for HPLC system I 
62 parts MeOH 
38 parts citric acid buffer 
 
A.3.4 Filtration 
BD Plastipak 5ml sterile syringe from Becton Dickinson S.A., fitted with 
Spartan 13/0.45 RC, 0.45µm filters from Whatman. 
 
A.3.5 Detection of the water content in RMβCD: 
The water content of the CDs (ca. 2.8% w/w) was determined by heating the 
CDs to 130°C on a Sartorius analytical weight for 60 minutes, respectively, 
and calculating the water loss.  
The water-content was calculated according to the equation:  
(W1 - W2) / W1 x 100%, where W1 and W2 are the weights of the CDs 
before and after drying, respectively. 
The measurements were done in triplicates and the value used for 
concentration corrections was the average of the three parallels. 
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1 parallel:  
W1: 1.94478  W2: 1.89092     x=2.769465% 
2 parallel: 
W1: 1.73229  W2: 1.68409    x=2.782444% 
3 parallel: 
W1: 1.98667  W2: 1.933    x=2.701506% 
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A 4 All Solubility investigations 
A.4.1 Solublity of crystalline curcumin in 0.1-5% (w/v) of RMβCD, 
purified water 
 
 
A.4.2 Solublity of crystalline curcumin in 0.1-5% (w/v) of RMβCD, 
purified water containing 1% (v/v) ethanol 
 
67	  
	  
A.4.3 Solublity of crystalline curcumin in 0.1-5% (w/v) of RMβCD, 
phosphate buffer pH5 (0.1 M, ionic strength 0.085) 
 
 
A.4.4 Solublity of crystalline curcumin in 0.1-5% (w/v) of RMβCD, 
phosphate buffer pH5 (0.1 M, ionic strength 0.085) containing 1% 
(v/v) ethanol 
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A.4.5. Solublity of crystalline curcumin and solved curcumin in 0.1-
5% (w/v) of RMβCD, phosphate buffer pH5 (0.1 M, ionic strength 
0.085) 
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A.4.6 Solublity of crystalline curcumin in 0.1-5% (w/v) of RMβCD, 
0.1% (w/v) HPMC in water containing 1% (v/v) ethanol 
 
 
A.4.7 Solublity of crystalline curcumin in 0.1-5% (w/v) of RMβCD, 
0.1% (w/v) sodium alginate in water containing 1% (v/v) ethanol 
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